Literature DB >> 16844503

A survey on the prevalence of orofacial herpes in France: the INSTANT Study.

Gérard Lorette1, Anne Crochard, Viviane Mimaud, Pierre Wolkenstein, Jean-François Stalder, Abdelkader El Hasnaoui.   

Abstract

Orofacial herpes is a common benign disease suspected to significantly impact the quality of life (QOL) of affected subjects. The objective of this population-based study was to evaluate the annual prevalence of orofacial herpes in France, its epidemiology, and its impact on QOL. Face-to-face home interviews were conducted among a random sample of 10,263 adults. A screening questionnaire identified subjects with a history of orofacial herpes (or cold sore) during the past 12 months; then, subjects with herpes completed another questionnaire to further describe their disorder and its management, and the SF-36 questionnaire to assess their QOL. The annual prevalence of orofacial herpes was 14.8% (95% confidence interval 14.03; 15.47); it was significantly higher in women than in men (P < .001) and decreased with age (P < .001). Among subjects with herpes, only 23% were aware of their disease. Tiredness and emotional stress were the main triggering events. There was no detectable difference between subjects with herpes and controls on SF-36 scores; however, when compared with subjects with 1 to 5 episodes per year, subjects with 6 or more episodes per year had significantly lower QOL scores.

Entities:  

Mesh:

Year:  2006        PMID: 16844503     DOI: 10.1016/j.jaad.2005.10.014

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  Current management and recommendations for access to antiviral therapy of herpes labialis.

Authors:  Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley
Journal:  J Clin Virol       Date:  2011-09-01       Impact factor: 3.168

2.  T-cell Responses to HSV-1 in Persons Who Have Survived Childhood Herpes Simplex Encephalitis.

Authors:  Mariliis Ott; Lichen Jing; Lazaro Lorenzo; Jean-Laurent Casanova; Shen-Ying Zhang; David M Koelle
Journal:  Pediatr Infect Dis J       Date:  2017-08       Impact factor: 2.129

3.  [Acute retinal necrosis from the virologist's perspective].

Authors:  P Rautenberg; L Grancicova; J Hillenkamp; B Nölle; J B Roider; H Fickenscher
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

4.  Fewer latent herpes simplex virus type 1 and cytotoxic T cells occur in the ophthalmic division than in the maxillary and mandibular divisions of the human trigeminal ganglion and nerve.

Authors:  Katharina Hüfner; Anja Horn; Tobias Derfuss; Christine Glon; Inga Sinicina; Viktor Arbusow; Michael Strupp; Thomas Brandt; Diethilde Theil
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

5.  Immune characteristics correlating with HSV-1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes.

Authors:  Hugh McTavish; Katherine W Zerebiec; Jay C Zeller; Laurie L Shekels; Mark A Matson; Betsy T Kren
Journal:  Immun Inflamm Dis       Date:  2019-02-12

6.  Antiherpetic drugs: a potential way to prevent Alzheimer's disease?

Authors:  Morgane Linard; Julien Bezin; Emilie Hucteau; Pierre Joly; Isabelle Garrigue; Jean-François Dartigues; Antoine Pariente; Catherine Helmer
Journal:  Alzheimers Res Ther       Date:  2022-01-07       Impact factor: 6.982

7.  Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology.

Authors:  Sapna Modi; Livia Van; Aron Gewirtzman; Natalia Mendoza; Brenda Bartlett; Anne Marie Tremaine; Stephen Tyring
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

8.  Herpes simplex virus type I-infected disorders alter the balance between Treg and Th17 cells in recurrent herpes labialis patients.

Authors:  Xian-Xian Mei; Shan-Shan Lei; Li Xu; Shan Wu; Huan-Peng Gu; Yu Du; Ting Zhao; Guan-Qun Xie; Yong-Sheng Fan; Xiao-Ping Pan; Jie Bao
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.